Shore Capital Reiterates “Hold” Rating for Vectura Group (LON:VEC)
Vectura Group (LON:VEC)‘s stock had its “hold” rating reiterated by equities researchers at Shore Capital in a research note issued on Tuesday, ThisIsMoney.Co.Uk reports.
Other analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. upped their price target on shares of Vectura Group from GBX 110 ($1.45) to GBX 120 ($1.58) and gave the company an “overweight” rating in a research report on Monday, January 6th. Peel Hunt reaffirmed a “buy” rating on shares of Vectura Group in a research report on Tuesday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Vectura Group has a consensus rating of “Buy” and a consensus target price of GBX 138.50 ($1.82).
VEC traded up GBX 5.30 ($0.07) during trading on Tuesday, reaching GBX 67.30 ($0.89). 2,261,018 shares of the stock traded hands, compared to its average volume of 4,610,000. The company has a quick ratio of 2.41, a current ratio of 2.84 and a debt-to-equity ratio of 1.73. The stock has a market capitalization of $408.34 million and a PE ratio of -5.26. The stock’s 50-day moving average is GBX 88.86 and its 200 day moving average is GBX 87.33. Vectura Group has a 12 month low of GBX 65.90 ($0.87) and a 12 month high of GBX 102.24 ($1.34).
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Further Reading: What are the benefits of momentum investing?
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.